Wednesday August 15, 2018 0 comments
The SBIR program enables scientific excellence and technological innovation by incentivizing small businesses to engage in commercial research and development.
The amount of the award was not disclosed.
KromaTID said the award will fund development of an automated, whole-genome directional Genomic Hybridization (dGH) platform.
KromaTiD's proprietary dGH is a single-cell structural genomics platform uniquely capable of de novo measurement of random, low frequency and complex structural variations.
By directly reading the genomic structure of many individual cells, dGH provides essential, quantitative structural variation data that cannot be measured through any other method.
The current, dGH platform was developed using SBIR funding from NASA as a sensitive method to assess genomic structural changes, caused by exposure to ionizing deep space radiation.
Based on that platform, KromaTiD said it now provides commercial dGH assays for detection of oncogenic fusions, discovery of disease-causing variants, biodosimetry and the measurements of structural off-target effects caused by gene editing.
With automated processing and whole genome structural analysis, KromaTiD said it will overcome the limitations of manual analysis, allowing dGH to provide the most comprehensive and definitive structural variation measurements possible.
"Through this SBIR award, the NIH is making it possible for KromaTiD to provide economical, whole genome analysis in thousands of single cells per sample -- enabling the discovery of rare structural variants and the measurement of extremely low levels of off-target structural damage in batches of edited cells," said Dr. Christopher Tompkins, KromaTID president and CTO.